Literature DB >> 33291571

Adaptive Immunity and Pathogenesis of Diabetes: Insights Provided by the α4-Integrin Deficient NOD Mouse.

Salim Oulghazi1, Sarah K Wegner1, Gabriele Spohn2, Nina Müller2, Sabine Harenkamp2, Albrecht Stenzinger3, Thalia Papayannopoulou4, Halvard Bonig1,2,4.   

Abstract

BACKGROUND: The spontaneously diabetic "non-obese diabetic" (NOD) mouse is a faithful model of human type-1 diabetes (T1D).
METHODS: Given the pivotal role of α4 integrin (CD49d) in other autoimmune diseases, we generated NOD mice with α4-deficient hematopoiesis (NOD.α4-/-) to study the role of α4 integrin in T1D.
RESULTS: NOD.α4-/- mice developed islet-specific T-cells and antibodies, albeit quantitatively less than α4+ counterparts. Nevertheless, NOD.α4-/- mice were completely and life-long protected from diabetes and insulitis. Moreover, transplantation with isogeneic α4-/- bone marrow prevented progression to T1D of pre-diabetic NOD.α4+ mice despite significant pre-existing islet cell injury. Transfer of α4+/CD3+, but not α4+/CD4+ splenocytes from diabetic to NOD.α4-/- mice induced diabetes with short latency. Despite an only modest contribution of adoptively transferred α4+/CD3+ cells to peripheral blood, pancreas-infiltrating T-cells were exclusively graft derived, i.e., α4+. Microbiota of diabetes-resistant NOD.α4-/- and pre-diabetic NOD.α4+ mice were identical. Co- housed diabetic NOD.α4+ mice showed the characteristic diabetic dysbiosis, implying causality of diabetes for dysbiosis. Incidentally, NOD.α4-/- mice were protected from autoimmune sialitis.
CONCLUSION: α4 is a potential target for primary or secondary prevention of T1D.

Entities:  

Keywords:  CD49d; VLA4; autoimmune diabetes; integrin; sialitis; type-1-diabetes

Year:  2020        PMID: 33291571      PMCID: PMC7761835          DOI: 10.3390/cells9122597

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  62 in total

Review 1.  The T cell receptor as a multicomponent signalling machine: CD4/CD8 coreceptors and CD45 in T cell activation.

Authors:  C A Janeway
Journal:  Annu Rev Immunol       Date:  1992       Impact factor: 28.527

Review 2.  The role of CD4 vs. CD8 T cells in IDDM.

Authors:  F S Wong; C A Janeway
Journal:  J Autoimmun       Date:  1999-11       Impact factor: 7.094

Review 3.  A comprehensive review of interventions in the NOD mouse and implications for translation.

Authors:  Lisl K M Shoda; Daniel L Young; Saroja Ramanujan; Chan C Whiting; Mark A Atkinson; Jeffrey A Bluestone; George S Eisenbarth; Diane Mathis; Aldo A Rossini; Scott E Campbell; Richard Kahn; Huub T C Kreuwel
Journal:  Immunity       Date:  2005-08       Impact factor: 31.745

4.  FastTree 2--approximately maximum-likelihood trees for large alignments.

Authors:  Morgan N Price; Paramvir S Dehal; Adam P Arkin
Journal:  PLoS One       Date:  2010-03-10       Impact factor: 3.240

5.  Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. 1991.

Authors:  Richard R Hardy; Condie E Carmack; Susan A Shinton; John D Kemp; Kyoko Hayakawa
Journal:  J Immunol       Date:  2012-10-01       Impact factor: 5.422

6.  Leukocytes infiltrating the pancreatic islets of nonobese diabetic mice are transformed into inactive exiles by combinational anti-cell adhesion therapy.

Authors:  S Kommajosyula; S Reddy; K Nitschke; J R Kanwar; M Karanam; G W Krissansen
Journal:  J Leukoc Biol       Date:  2001-10       Impact factor: 4.962

Review 7.  The role of the intestinal microbiota in type 1 diabetes mellitus.

Authors:  Mikael Knip; Heli Siljander
Journal:  Nat Rev Endocrinol       Date:  2016-01-04       Impact factor: 43.330

8.  Complement lytic activity has no role in the pathogenesis of autoimmune diabetes in NOD mice.

Authors:  A G Baxter; A Cooke
Journal:  Diabetes       Date:  1993-11       Impact factor: 9.461

9.  Non-obese diabetic (NOD) mice display enhanced immune responses and prolonged survival of lymphoid cells.

Authors:  K Leijon; B Hammarström; D Holmberg
Journal:  Int Immunol       Date:  1994-02       Impact factor: 4.823

10.  Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients.

Authors:  Jan W Traub; Hannah L Pellkofer; Katja Grondey; Ira Seeger; Christoph Rowold; Wolfgang Brück; Leila Husseini; Silke Häusser-Kinzel; Martin S Weber
Journal:  J Neuroinflammation       Date:  2019-11-16       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.